Prevention & lipids

A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance

Eur Heart J Cardiovasc PharmacotherPublished Genetic association study

Authors' conclusion

We provide evidence that a GRS based on four common SLCO1B1 variants provides an easily implemented genetic tool that is more reliable than the current recommended practice in estimating the risk and predicting early-onset statin intolerance.

Study context

Population
Statin users from Tayside, Scotland, UK
Comparison
High-risk SLCO1B1 gene risk score (GRS) vs low-risk GRS, compared with Val174Ala genotype alone or recommended OATP1B1 functional phenotypes
Outcome
Statin intolerance across three phenotypes: general statin intolerance (GSI), statin-related myopathy, statin-related suspected rhabdomyolysis

Main finding

As reported in the abstract

Statin intolerance phenotypes with high-risk GRS
High-risk GRS vs Low-risk GRSOdds ratio (95% CI)P value
General statin intolerance (GSI)
2.42(1.29–4.31)
P = 0.003
Statin-related myopathy
2.51(1.28–4.53)
P = 0.004
Statin-related suspected rhabdomyolysis
2.85(1.03–6.65)
P = 0.02

Further findings

Meta-analysis with adjudicated statin-induced myopathy cases (PREDICTION-ADR Consortium)

ORVal174Ala
1.99; 95% CI: 1.01-3.95, P = 0.048
ORGRS
1.76; 95% CI: 1.16-2.69, P = 0.008

Time to onset of general statin intolerance (GSI) in those requiring high-dose statin therapy

HRVal174Ala
2.49; 95% CI: 1.09-5.68, P = 0.03
HRGRS
2.44; 95% CI: 1.46-4.08, P < 0.001
High-risk GRS more consistently associated with time to onset across the three phenotypes than Val174Ala

Val174Ala alone or recommended OATP1B1 functional phenotypes

Weaker and less reliable results

Rare SLCO1B1 variants and risk of intolerance (sequence kernel association testing)

Rare variants in SLCO1B1 associated with risk of intolerance
P = 0.02

Original publication

A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance. Eur Heart J Cardiovasc Pharmacother. Published 30 May 2023. doi:10.1093/ehjcvp/pvad040

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.